High Q Technologies develops quantum-enabled scientific instruments—notably Electron Paramagnetic Resonance (EPR) spectroscopy systems—for protein characterization used in drug discovery. The company’s core product family targets study of protein dynamics to support pharmaceutical and biotechnology applications. Recent funding is intended to accelerate product development and commercialization of these EPR systems into the larger pharmaceutical and drug-discovery market. The firm says improved access to cutting-edge EPR spectroscopy will help researchers better understand protein dynamics and speed therapeutic discovery. High Q previously received a $6.5 million federal investment in 2019 to support early R&D of quantum sensor technologies that underpinned its core capabilities.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2024